We use cookies to ensure our website works properly and to personalise your experience. Cookies policy
1Research Scholar, Maharishi Arvind Institute of Pharmacy, Jaipur, Rajasthan, India
2Associate Professor, Maharishi Arvind Institute of Pharmacy, Jaipur, Rajasthan, India
3Principal, Maharishi Arvind Institute of Pharmacy, Jaipur, Rajasthan, India
Fungal infections caused by Candida species represent a critical global healthcare challenge due to the rising prevalence of immunocompromised host conditions and increasing resistance to conventional antifungal agents. Synthetic therapies—including azoles, echinocandins, and polyenes—are frequently limited by host toxicity, adverse drug interactions, high costs, and the rapid emergence of multidrug-resistant strains like Candida auris. Consequently, plant-based secondary metabolites have gained attention as alternative or synergistic therapeutic agents. This review provides a comprehensive synthesis of the pathogenic burden of candidiasis, mechanisms of current antifungal classes, and the therapeutic efficacy of Nigella sativa Linn. and Catharanthus roseus Linn. Active constituents such as thymoquinone (N. sativa) and indole alkaloids (C. roseus) demonstrate distinct multi-target antimicrobial mechanisms. Pharmacological evaluation highlights the superior antifungal potency of N. sativa extracts over C. roseus against various clinical Candida strains. Furthermore, current research gaps, standardization challenges, and future clinical integration strategies are critically evaluated.
1.1 Global Burden and High-Risk Populations
Fungal diseases, long underreported in comparison to bacterial and viral infections, have emerged as a primary cause of global morbidity and mortality. Opportunistic Candida infections span from non-life-threatening superficial mucosal lesions (e.g., oral thrush, vulvovaginal candidiasis, cutaneous manifestations) to invasive systemic candidemia causing multi-organ failure and sepsis.
The growing population of susceptible individuals stems from modern medical interventions, including:
1.2 Genus Candida: Commensal to Pathogen
Candida yeasts exist as harmless commensals in human oral cavity, gastrointestinal, and vaginal mucosal flora. Transition to pathogenic states relies on virulence factors such as dimorphic switching (morphological alteration between yeast and invasive hyphae), cell surface adhesins, hydrolytic tissue-degrading enzymes (proteases, lipases), and dense biofilm formation on mucosal tissues and indwelling medical devices. While Candida albicans remains the primary isolate, non-albicans species—including Candida glabrata (azole tolerance), Candida tropicalis, Candida parapsilosis, Candida krusei (intrinsic fluconazole resistance), and Candida auris (multidrug-resistant nosocomial threat)—present substantial therapeutic hurdles.
1.3 Synthetic Antifungals: Mechanisms & Limitations
Current clinical management relies on five major classes of synthetic antifungal drugs:
| Antifungal Class | Representative Drugs | Target Mechanism | Primary Limitations & Toxicities |
|---|---|---|---|
| Azoles | Fluconazole, Itraconazole, Voriconazole | Inhibits lanosterol 14-α-demethylase, blocking ergosterol synthesis | Hepatotoxicity, visual disturbances, drug interactions; widespread acquired resistance |
| Echinocandins | Caspofungin, Micafungin, Anidulafungin | Inhibits β-(1,3)-D-glucan synthase, disrupting cell wall integrity | Lack of oral formulations; low activity against Cryptococcus or molds; emerging FKS gene mutations |
| Polyenes | Amphotericin B, Nystatin | Binds ergosterol, forming transmembrane pores and inducing leakage | Severe nephrotoxicity, infusion reactions, electrolyte imbalances |
| Flucytosine | 5-Fluorocytosine | Inhibits thymidylate synthase, halting fungal DNA/RNA synthesis | Rapid resistance emergence; narrow monotherapy spectrum |
| Allylamines | Terbinafine | Inhibits squalene epoxidase in ergosterol pathway | Ineffective against systemic deep-tissue mycoses |
2. Botanicals as Novel Antifungal Candidates
Due to the toxicity, high costs, and single-target mechanisms of synthetic drugs that accelerate fungal resistance, bioactive plant extracts offer a compelling alternative. Plant secondary metabolites act through multifaceted mechanisms—simultaneously targeting cell membranes, cell walls, nucleic acid synthesis, metabolic pathways, and oxidative stress pathways—thereby reducing the likelihood of cross-resistance.
2.1 Nigella sativa Linn. (Black Seed)
Nigella sativa (Ranunculaceae family) contains a rich spectrum of bioactives, including essential oils, fixed oils, saponins, and alkaloids.
2.2 Catharanthus roseus Linn. (Madagascar Periwinkle)
Catharanthus roseus (Apocynaceae family) produces over 130 terpenoid indole alkaloids alongside flavonoids, saponins, and phenolic glycosides.
3. Current Challenges & Future Perspectives
3.1 Analytical and Methodological Gaps
3.2 Research Roadmap and Clinical Integration
1. Advanced Extraction & Green Chemistry: Utilize supercritical CO2 fluid extraction and nano-encapsulation to improve active yield, chemical stability, and target tissue delivery.
2. Combination Therapies: Investigate synergistic pairings of thymoquinone or vinca alkaloids with sub-inhibitory doses of fluconazole or amphotericin B to restore drug sensitivity and reduce host toxicity.
3. In Vivo Models & Clinical Trials: Conduct pharmacokinetic/pharmacodynamic (PK/PD) profiling and safety assays in animal models to establish human safety margins and clinical efficacy.
CONCLUSION
Candida infections and increasing antifungal resistance highlight the need for safer and more effective therapeutic alternatives. Nigella sativa and Catharanthus roseus contain diverse bioactive compounds with promising antifungal, antioxidant, and antimicrobial properties. Among these, thymoquinone from N. sativa shows considerable potential through membrane disruption and biofilm inhibition. However, further standardized phytochemical, in vivo, pharmacokinetic, and clinical studies are required to establish their safety and therapeutic efficacy.
REFERENCES
Najrana, Richa Agarwal, Rajesh Asija, Comprehensive Review on Plant-Derived Antifungals: Nigella Sativa and Catharanthus Roseus Against Opportunistic Candida Infections, Int. J. Med. Pharm. Sci., 2026, 2 (11), 107-110. https://doi.org/10.5281/zenodo.24414658
10.5281/zenodo.24414658